NCT05633160: An ongoing trial by Clarity Pharmaceuticals Ltd
This trial is ongoing. It must report results 1 year, 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05633160 |
|---|---|
| Title | A Phase I/IIa Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 15, 2023 |
| Completion date | May 31, 2026 |
| Required reporting date | May 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 12, 2025 |
| Days late | None |